You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy
|
|---|---|
| Published in |
Journal of Experimental & Clinical Cancer Research, September 2008
|
| DOI | 10.1186/1756-9966-27-40 |
| Pubmed ID | |
| Authors |
Alan B Weitberg |
| Abstract |
Beta-(1,3)/(1,6) D-glucan, a component of the fungal cell wall, has been shown to stimulate the immune system, enhance hematopoiesis, amplify killing of opsonized tumor cells and increase neutrophil chemotaxis and adhesion. In view of these attributes, the beta-glucans should be studied for both their therapeutic efficacy in patients with cancer as well as an adjunctive therapy in patients receiving chemotherapy as a maneuver to limit suppression of hematopoiesis.In this study, twenty patients with advanced malignancies receiving chemotherapy were given a beta-(1,3)/(1,6) D-glucan preparation (MacroForce plus IP6, ImmuDyne, Inc.) and monitored for tolerability and effect on hematopoiesis. Our results lead us to conclude that beta-glucan is well-tolerated in cancer patients receiving chemotherapy, may have a beneficial effect on hematopoiesis in these patients and should be studied further, especially in patients with chronic lymphocytic leukemia and lymphoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| United States | 1 | 1% |
| Australia | 1 | 1% |
| Unknown | 77 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 29% |
| Student > Master | 8 | 10% |
| Other | 7 | 9% |
| Student > Bachelor | 5 | 6% |
| Professor > Associate Professor | 5 | 6% |
| Other | 16 | 20% |
| Unknown | 16 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 28% |
| Agricultural and Biological Sciences | 18 | 23% |
| Chemistry | 4 | 5% |
| Immunology and Microbiology | 4 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Other | 9 | 11% |
| Unknown | 20 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2021.
All research outputs
#4,168,596
of 25,374,917 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#221
of 2,379 outputs
Outputs of similar age
#15,686
of 98,896 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#2
of 7 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,379 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 98,896 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.